Navigation Links
Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
Date:3/30/2009

pleted on a timely basis; the possibility that the acquisition of Indevus is not complimentary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connection with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in many of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; our ability to protect our proprietary technology; our ability to successfully implement our in-licensing and acquisition strategy; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by the government; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total net sales; a determination by a regulatory agency that we are engaging in inappropriate sales or marketing activities, including promoting the "off-label" use of our products; the loss of branded product exclusivity periods and related intellectual property; and exposure to securities that are subject to market risk including auction-rate securities the market for which is currently illiquid; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... RALEIGH, N.C. , Aug. 20, 2014 /PRNewswire/ ... clinical research services located in Raleigh, ... Bradford Evans as Vice President of ... Administration, Brad will oversee all corporate processes, including ... to joining Clintrax Global, Brad worked as an ...
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
(Date:8/20/2014)... -- Decision Resources Group finds that the vascular access device market in ... India and China (BRIC) ... the size of the United States market ... faster growth as a result of strong economic expansion, improving access ... from Decision Resources Group,s coverage of the BRIC vascular access device ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... N.J., Sept. 12 Schering-Plough,Corporation (NYSE: SGP ) ... aggregate principal amount of 6.00% Senior Notes due 2017 ... due 2037 through,an underwritten registered public offering. The offering ... customary closing conditions. The global coordinator for the ...
... Inc.,(Nasdaq: MEDX ) announced today that it is ... Growth Conference in New York City on Tuesday,September 18, ... be,webcast live and will be available for replay through ... Medarex website via the Internet at, http://www.medarex.com . ...
... SAN DIEGO, Sept. 12 Gen-Probe Incorporated,(Nasdaq: GPRO ... Bank of,America,s 37th Annual Investment Conference in San Francisco ... (5:30 p.m. Eastern Time).,The presentation is scheduled to be ... the investor information section of Gen-Probe,s website,at http://www.gen-probe.com ...
Cached Biology Technology:Schering-Plough Announces Pricing of Senior Notes Offering 2Schering-Plough Announces Pricing of Senior Notes Offering 3Gen-Probe to Webcast Presentation at Bank of America's 37th Annual Investment Conference 2
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... the journal Carcinogenesis by researchers at the ... protein adenomatous polyposis coli (APC) in suppressing colorectal cancer ... U.S. , Lead author Kristi Neufeld, associate professor in ... Cancer Biology program at the KU Cancer Center, has ... understand the various activities of APC, a protein whose ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3New feeding tube connectors will improve patient safety 2
... at Universitat Autnoma de Barcelona (INc-UAB) identified the fundamental ... associated with synaptic activity. The discovery, published in the ... study a new target that could help to understand ... known to cause early cognitive deficit, and the neurodegeneration ...
... NC In a paper published today in the journal ... North Carolina at Chapel Hill demonstrates a simple, cost-effective technique ... the structures, and ultimately the functions, of the RNA molecules ... When cell behavior goes wrong, diseases including cancer and ...
... gene sequencing technology, researchers have demonstrated that the gene ... Leukemia, AML, one of the most common types of ... allows for the rapid and comprehensive detection of gene ... online April 15 in Nature , are a ...
Cached Biology News:Researchers have identified a gene with a key role in neuronal survival 23-D RNA modeling opens scientific doors 2Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
... U. Desselberger (1995) • This book ... together classical and molecular techniques currently ... infections and analysis of virus-specific antibodies ... are presented covering immunoassays, blotting and ...
...
... Kits provide rapid and efficient removal of ... and salts from PCR products (Figure 1). ... two Binding Buffer options for fragments >100 ... performed in either single column or 96-well ...
... Blunt TOPO PCR Cloning Kit offers ... high-efficiency (>=95%) cloning of blunt-end PCR ... The kit includes the linearized and ... 5-minute bench-top ligations without ligase (1). ...
Biology Products: